GIP and GLP-1 receptor co-agonist
Tirzepatide maximum tolerated dose injection once weekly
TIRZ_SC_MTD_5-10-15_QW
Related
- All doses pooled: Tirzepatide injection
- Tirzepatide 1 mg subcutaneous once weekly
- Tirzepatide 5 mg subcutaneous once weekly
- Tirzepatide 10 mg subcutaneous once weekly
- Tirzepatide 15 mg subcutaneous once weekly
- Tirzepatide subcutaneous once weekly, maximum tolerated dose: 10 or 15 mg
- Tirzepatide 12 mg injection once weekly
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Standard care or no added treatment | MD -7.63 (-13.38 to -1.18) | 0.98 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Standard care or no added treatment | MD -14.96 (-19.90 to -9.21) | 1.00 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.38 (0.11 to 1.30) | 0.79 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.49 (0.02 to 9.38) | 0.73 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.70 (0.10 to 3.25) | 0.89 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.43 (0.17 to 9.65) | 0.76 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.41 (0.07 to 2.08) | 0.88 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.03 (0.43 to 9.76) | 0.49 |
Trials
- TOGETHER-PsOEfficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsO)2024 · 281 randomized · 52 weeks
- TOGETHER-PsAEfficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Active Psoriatic Arthritis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsA)2024 · 279 randomized · 52 weeks